by Marisa Wexler, MS | Dec 17, 2025 | Myeloma News
A Phase 1 clinical trial testing the experimental therapy IDE034 in people with various types of cancer, including gynecological cancers, is expected to start in the first quarter of 2026. The trial is being conducted by Ideaya Biosciences, which is developing IDE034...
by MM360 Staff | Dec 17, 2025 | Myeloma News
Source: Pharmacy Times articles Post Content Read More
by Marisa Wexler, MS | Dec 16, 2025 | Myeloma News
Johnson & Johnson (J&J) is asking the U.S. Food and Drug Administration (FDA) to approve a combination of two medications, Tecvayli (teclistamab) and Darzalex Faspro (daratumumab and hyaluronidase-fihj), for people with relapsed or refractory, or...
by Mark Leiser | Dec 15, 2025 | Uncategorized
ORLANDO — An in vivo chimeric antigen receptor T-cell therapy administered without lymphodepletion exhibited activity among patients with advanced multiple myeloma, according to findings presented at ASH Annual Meeting and Exposition.The first four patients treated...
by Andrea Lobo | Dec 15, 2025 | Myeloma News
The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to SENTI-202, Senti Biosciences‘ experimental cell therapy being developed for adults with hard-to-treat blood cancers, including acute myeloid leukemia...
